

332 patients with metastatic disease (100%)
Temporality: Synchronous metastasis (n=216), Metachronous metastasis (n=116)

No 1st line (n=70)
-> Reduced performance status (n=42)
-> Unknown (n=18)
-> Declined therapy (n=9)
-> Other reasons (n=2)

262 patients undergoing 1st line therapy
231 entering analysis (100%)
Most frequent therapies: FOLFOX (n=46), Capecitabine (n=35), FOLFOX+Bev (n=41)

CR (n=4 (2%))

PR (n=59 (26%))

SD (n=61 (26%))

PD (n=66 (29%))

NE (n=40 (17%))

No 2nd line (n=110)
-> Reduced performance status (n=56)
-> Still receiving 1st line at documentation (n=12)
-> Unknown (n=29)

152 patients undergoing 2nd line therapy
117 entering analysis (100%)
Most frequent therapies: FOLFIRI+Bev (n=21), FOLFIRI (n=16), FOLFOX+Bev (n=15)

CR (n=0 (0%))

PR (n=24 (21%))

SD (n=32 (27%))

PD (n=42 (36%))

NE (n=19 (16%))

No 3rd line (n=81)
-> Reduced performance status (n=36)
-> Still receiving 2nd line at documentation (n=15)
-> Unknown (n=14)

71 patients undergoing 3rd line therapy
55 entering analysis (100%)
Most frequent therapies: Irinotecan+aEGFR (n=8), FOLFIRI+Bev (n=7), aEGFR Monotherapy (n=6)

CR (n=1 (2%))

PR (n=87 (13%))

SD (n=10 (18%))

PD (n=25 (45%))

NE (n=12 (22%))